Novo Holdings, the investment firm behind pharmaceutical giant Novo Nordisk, is committing $25 million over five years to a new, early-stage biotech incubator at the Broad Institute, a research center affiliated with both Harvard and MIT.
Novo Holdings’ commitment is the latest example of an ongoing push among biotech venture capitalists to invest in younger and younger startups.
About the Author Reprints
